STK11 and neoplasm: Apart from PD-L1 expression, more predictive biomarkers or prognostic factors, including but not limited to blood-based tumor mutational burden (bTMB), high body mass index (BMI), lactate dehydrogenase level (LDH), lung immune prognostic index (LIPI), serine/threonine kinase 11 gene (STK11) mutation, STING pathway, should be further analyzed to help identify the most effective treatment regimens for this specific population (17–21).